“Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study”. SKIN The Journal of Cutaneous Medicine 4, no. 6 (October 27, 2020): s82. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/1115.